Handok (002390.KS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7002390003

Price
8,320.00 KRW
Market cap
108.08 bn KRW
P/E (2025)
–
P/S (2025)
0.20
Dividend yield
2.40 %
Net margin
-0.40 %
Return on equity (ROE)
-0.78 %
Return on assets (ROA)
-0.27 %

Handok financials

Fiscal year20242025
Revenue507.36 bn KRW535.14 bn KRW
Gross profit157.41 bn KRW158.93 bn KRW
Operating income538.51 m KRW3.29 bn KRW
EBIT-44.36 bn KRW12.00 bn KRW
Net income-52.56 bn KRW-2.15 bn KRW
Diluted EPS – continuing operations-3,818.99 KRW-165.73 KRW

Full history since 2011, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Handok

HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food supplements under the NatureSet brand; food and beverages; and medical nutrition products. In addition, the company engages in real estate leasing. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.